This page shows results related to Aclasta and Cardiac Failure from the FDA Adverse Event Reporting System (AERS).Click here to learn about all Aclasta adverse events.
What were the most common outcomes of those reporting Cardiac Failure?
Who most commonly reported Cardiac Failure?
Of those reporting Cardiac Failure, why were they taking Aclasta?
Which medications reported to the FDA are most commonly associated with Cardiac Failure?
The Naranjo Scale is a questionnaire for determining the likelihood of whether an adverse drug reaction is actually due to the drug or caused by other factors. Probability is assigned via a score termed definite, probable, possible or doubtful.*
|Are there previous conclusive reports on this reaction?|
|Did the adverse event appear after the suspected drug was administered?|
|Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered?|
|Did the adverse reaction reappear when the drug was readministered?|
|Are there alternative causes (other than the drug) that could on their own have caused the reaction?|
|Did the reaction reappear when a placebo was given?|
|Was the drug detected in the blood (or other fluids) in concentrations known to be toxic?|
|Was the reaction more severe when the dose was increased, or less severe when the dose was decreased?|
|Did the patient have a similar reaction to the same or similar drugs in any previous exposure?|
|Was the adverse event confirmed by any objective evidence?|
*Naranjo, et al. "A method for estimating the probability of adverse drug reactions." Clin Pharmacol Ther. 1981 Aug;30(2):239-45.
To learn more about all adverse events for Aclasta, view the complete Aclasta adverse event report.
Share your experience with Aclasta and Cardiac Failure.